吉西也滨联合长瑞滨、地塞米松在复发性非霍奇金淋巴瘤治疗中的作用

Gemcitabine in combination with vinorelbine and dexamethasone for relapsed non-Hodgkin＇s lymphoma

目的 探讨吉西他滨联合长春瑞滨、地塞米松治疗复发性非霍奇金淋巴瘤的临床价值.方法 将18例复方性非霍奇金淋巴瘤作为研究对象,所有患者均采用盐酸吉西他滨联合长春瑞滨、地塞米松的化疗方案,观察患者的疗效、不良反应及随访肿瘤的进展时间.结果 复发性非霍奇金淋巴瘤的整体有效率为55.56％,完全缓解率为22.22％,在B细胞、T细胞分类上疗效未见统计学意义（x 2=0.969,P=0.809）;常见的毒性作用以骨髓抑制为主,5例患者出现胃肠道反应,1例出现轻度肝功能损害;进行2年的随访后10例患者未出现肿瘤进展,8例患者（44.4％）的肿瘤进展时间（TTP）为4.9个月.结论 采用吉西他滨联合长春瑞滨、地塞米松对复发性非霍奇金淋巴瘤的治疗近期疗效确切、不良反应较轻,拥有较低的复发率.

Objective To explore the clinical value of Gemcitabine in combination with vinorelbine and dexamethasone in the treatment of relapsed non-Hodgkin＇s lymphoma. Methods 18 patients with non- Hodgkin＇s lymphoma were treated with gemcitabine hydroehloride, Vinorelbine , and dexamethasone. The efficacy, adverse reactions, and tumor progression were observed. Results The overall effective rate was 55.56%. The complete remission rate was 22.22%. There was no statistical difference（x 2 = 0.969, P = 0.809） in classification between B and T cells. Bone marrow suppression was the common toxicity. 5 patients had gastrointestinal reactions. 1 patient occurred mild liver dysfunction. After two years follow-up, it showed that 10 patients had no tumor progression, the other 8 patients （44.4%） progressed in tumor in average 4.9 months. Conclusions Gemcitabine in combination with vinorelbine and dexamethasone for non-Hodgkin＇s lymphoma has a good recent efficacy, few adverse reactions, and a low recurrence rate.